Evidence map›Paper›PMID 34403862›Full record

ArticleJournal of neuroimmunology2021

Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.

Emma E Kraus, Laura Kakuk-Atkins, Marissa F Farinas, Matthew Jeffers, Amy E Lovett-Racke, Yuhong Yang

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' DiseaseEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  4. Article
  5. Foxp3Research square · 2025
    Article
  6. Pseudokinase STK40 promotes TScience advances · 2024
    Article
  7. miR-132-3p downregulatesThe Journal of international medical research · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emma E KrausDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States of America.
Laura Kakuk-AtkinsDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States of America.
Marissa F FarinasNeuroscience program, College of Arts and Sciences, The Ohio State University, Columbus, OH 43210, United States of America.
Matthew JeffersNeuroscience program, College of Arts and Sciences, The Ohio State University, Columbus, OH 43210, United States of America.
Amy E Lovett-RackeDepartment of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States of America.
Yuhong YangDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States of America; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States of America. Electronic address: yuhong.yang@osumc.edu.
The Ohio State University Wexner Medical Center · USFlorida State University · US

Funding

Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapyR01NS088437 · NINDS · UNIVERSITY OF FLORIDA · PI LI, CHENGLONG, YANG, YUHONG · 2015 to 2017
$1.3M
NINDS NIH HHS R01 NS088437
6 · The paper itself

Abstract

Myelin-specific CD4 T effector cells (Teffs), Th1 and Th17 cells, are encephalitogenic in experimental autoimmune encephalomyelitis (EAE), a well-defined murine model of multiple sclerosis (MS) and implicated in MS pathogenesis. Forkhead box O 1 (FoxO1) is a conserved effector molecule in PI3K/Akt signaling and critical in the differentiation of CD4 T cells into T helper subsets. However, it is unclear whether FoxO1 may be a target for redirecting CD4 T cell differentiation and benefit CNS autoimmunity. Using a selective FoxO1 inhibitor AS1842856, we show that inhibition of FoxO1 suppressed the differentiation and expansion of Th1 cells. The transdifferentiation of Th17 cells into encephalitogenic Th1-like cells was suppressed by FoxO1 inhibition upon reactivation of myelin-specific CD4 T cells from EAE mice. The transcriptional balance skewed from the Th1 transcription factor T-bet toward the Treg transcription factor Foxp3. Myelin-specific CD4 T cells treated with the FoxO1 inhibitor were less encephalitogenic in adoptive transfer EAE studies. Inhibition of FoxO1 in T cells from MS patients significantly suppressed the expansion of Th1 cells. Furthermore, FoxO1 inhibition with AS1842856 promoted the development of functional iTreg cells. The immune checkpoint programmed cell death protein-1 (PD-1)-induced Foxp3 expression in CD4 T cells was impaired by FoxO1 inhibition. These data illustrate an important role of FoxO1 signaling in CNS autoimmunity via regulating autoreactive Teff and Treg balance.

Indexed as

AdultAnimalsAutoimmunityCD4-Positive T-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalFemaleForkhead Box Protein O1HumansMaleMiceMice, Inbred C57BLMice, TransgenicMiddle AgedMultiple SclerosisQuinolones5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acidForkhead Box Protein O1FOXO1 protein, humanQuinolonesAS1842856Central Nervous System (CNS)Experimental autoimmune encephalomyelitis (EAE)Forkhead box O 1 (FoxO1)Multiple Sclerosis (MS)T effector cellsT regulatory cells

Identifiers

PMID34403862
PMCPMC8435019
OpenAlexW3137453950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.